Dishman Carbogen Amcis

Ahmedabad, India Founded: 1983 • Age: 43 yrs Listed
Active pharmaceutical ingredients are manufactured by the CDMO in India.

About Dishman Carbogen Amcis

Dishman Carbogen Amcis is a publicly listed company based in Ahmedabad (India) founded in 1983 by Janmejay R Vyas. Active pharmaceutical ingredients are manufactured by the CDMO in India. The company has 1,122 employees. Its website imdcal.com draws about 17 thousand monthly visits. Its Indian entity Dishman Carbogen Amcis Limited reported revenue of β‚Ή2,988 Cr. Dishman Carbogen Amcis offers products and services including CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Dishman Carbogen Amcis was established in 1983 in Ahmedabad, India, by founder Janmejay R Vyas. Operations are centered on contract development and manufacturing services for active pharmaceutical ingredients within the pharmaceutical sector. Production facilities are maintained in India, supporting API synthesis and related processes for international clients. The focus remains on reliable manufacturing capabilities without additional diversification noted.

  • Headquarters Ahmedabad, India
  • Employees 1,122
  • Founders Janmejay R Vyas
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website imdcal.com
  • Social LinkedIn
  • Legal Name Dishman Carbogen Amcis Ltd.
Key Metrics
  • Market Cap
    ₹1,858 Cr

    DCAL · NSE

  • Share Price
    ₹115.90

    -2.22% today

  • Revenue
    ₹2,932 Cr

    FY 2025-26 · +8.1% YoY

  • EBITDA
    ₹562 Cr

    Margin 19.2%

  • Net Profit
    ₹98.68 Cr

    FY 2025-26 · +639.8% YoY

  • ROE
    1.6%

    ROCE 2.8%

  • Debt / Equity
    0.44

    Interest cover 78.1x

  • Employee Count
    1,122

Products & Services of Dishman Carbogen Amcis

Dishman Carbogen Amcis offers a comprehensive portfolio of products and services, including CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts.

CRAMS Services
Development Services

Offers contract research for pharmaceutical API development.

API Manufacturing
Manufacturing Services

Provides highly potent API supply and production.

Analytical Capabilities
Testing Services

Delivers quality analysis for pharmaceutical products.

Finished Dosages
Product Solutions

Includes health and personal care formulations.

Quaternary Salts
Chemical Products

Specializes in encapsulation and formulation capabilities.

Board of directors of Dishman Carbogen Amcis Limited (Dishman Carbogen Amcis)

Dishman Carbogen Amcis Limited is the primary company behind Dishman Carbogen Amcis. The board of Dishman Carbogen Amcis Limited currently have 7 directors; the longest-serving is Arpit Janmejay Vyas, appointed in 2012. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Arpit Janmejay Vyas
DIN 01540057
Managing Director07 Apr 201214 yrs 7 moDishman Carbogen Amcis Limited
Deohooti Janmejay Vyas
DIN 00004876
Whole-time director17 Mar 20179 yrs 8 moDishman Carbogen Amcis Limited
Harshil Ramakant Dalal
DIN 06481203
CFO28 Nov 20187 yrs 11 moDishman Carbogen Amcis Limited
Kulin Nalinkant Shah
DIN 01863481
Director13 Nov 20242 yrsDishman Carbogen Amcis Limited
Hemantkumar Jayantiprasad Bhatt
DIN 02657432
Director01 Apr 20251 yr 7 moDishman Carbogen Amcis Limited
Margie Parikh
DIN 07056179
Director01 Apr 20251 yr 7 moDishman Carbogen Amcis Limited
Dhaval Rameshchandra Shah
DIN 09385325
Director12 Aug 20251 yr 3 moDishman Carbogen Amcis Limited

People of Dishman Carbogen Amcis

10 people are tracked at Dishman Carbogen Amcis (10 in leadership); the tracked headcount is 1,122.

NameRoleGroup
FounderLeadership
Pascal Villemagne
Chief Executive Officer (carbogen Amcis)Leadership
Global Managing DirectorLeadership
Paolo Armanino
Chief Operating Officer IndiaLeadership
Stephan Fritschi
Executive Vice-president Business Units; Deputy CEO (carbogen Amcis)Leadership
Alan Fischer
Vice President Innovation & M&a (carbogen Amcis)Leadership
François Baduel
Vice President Sales & Marketing (carbogen Amcis)Leadership
Martin Schneider
Vice President Quality & ESH (carbogen Amcis)Leadership
Global Chief Financial OfficerLeadership
Dieter Thüer
Vice President Human Resources (carbogen Amcis)Leadership
Premium access

Complete people profiles for Dishman Carbogen Amcis

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Dishman Carbogen Amcis

Dishman Carbogen Amcis is a publicly listed company on the NSE with ticker symbol DCAL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Sep 2017
  • Listed onNSE: DCAL · BSE: 540701
  • Listed entityDishman Carbogen Amcis Ltd.
  • Exchange sectorHealth technology
  • ISININE385W01011
  • Share price₹153.04 (+1.65% on the day) · 2026-10-14
  • Market capitalisation₹2,365 Cr
  • Price to earnings35.2
  • EPS (diluted, trailing year)₹4.35
  • Volume (last session)143,223

Financials of Dishman Carbogen Amcis

Exchange-reported figures of Dishman Carbogen Amcis Limited, the listed company behind Dishman Carbogen Amcis (NSE: DCAL).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹2,932 Cr
+8.1% YoY
EBITDA
₹562 Cr
+24.6% YoY
Profit After Tax
₹98.68 Cr
+639.8% YoY
Net Worth
₹6,677 Cr
+14.5% YoY
Total Assets
₹10,912 Cr
+20.4% YoY
Total Debt
₹3,076 Cr
+28.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,9322,7122,6162,4132,1411,9122,044
Revenue growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
EBITDA562451280284317252498
EBITDA margin+19.2%+16.6%+10.7%+11.8%+14.8%+13.2%+24.4%
Profit before tax10519.31(122)(54.59)(4.25)(65.03)197
Net profit98.68(18.28)(151)(8.36)49.61(170)163
Net profit margin+3.4%-0.7%-5.8%-0.4%+2.3%-8.9%+8.0%
EPS (β‚Ή)6.210.21(9.79)(1.90)1.15(10.53)10.10
Balance sheet
Total assets10,9129,0628,7688,4197,8097,6047,367
Net worth6,6775,8325,6285,8105,5495,6995,715
Total debt3,0762,3892,3132,2091,8301,5891,357
Cash & bank991507413189172308161
Net working capital1,8271,2501,1317828461,017984
Cash flow
Cash from operations491371379266355513585
Cash from investing(245)(192)(225)(494)(619)(380)(442)
Cash from financing201(102)(22.15)250130(11.04)(97.78)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue507678851720653708716682
Revenue growth (YoY)-22.3%-4.3%+18.9%+5.5%-17.3%+35.2%--
Other income3.5618.1616.426.668.1124.757.977.67
EBITDA45.9658.39162113149138141140
EBITDA margin+9.1%+8.6%+19.0%+15.7%+22.8%+19.5%+19.7%+20.5%
Depreciation90.4290.6888.7984.4284.1381.3579.0971.97
Interest40.1037.0943.3045.7942.3342.7642.1248.78
Profit before tax(81.00)(51.22)46.13(10.44)30.5438.6727.7027.05
Tax(14.27)6.6624.392.53(34.73)15.26(15.39)22.42
Net profit(66.73)(57.88)21.74(12.97)65.2723.4143.094.63
EPS (β‚Ή)(4.26)(3.69)1.39(0.83)4.161.492.750.30
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue232400327403307200581
Revenue growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
EBITDA5.3271.793.755.7632.52(59.32)174
EBITDA margin+2.3%+18.0%+1.2%+1.4%+10.6%-29.6%+29.9%
Profit before tax(59.25)(30.83)(103)(96.20)(84.39)(169)55.46
Net profit(39.53)(11.18)(75.39)(56.08)(30.76)(235)42.58
Net profit margin-17.1%-2.8%-23.0%-13.9%-10.0%-117.5%+7.3%
EPS (β‚Ή)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
Balance sheet
Total assets4,7674,8924,7874,9104,9465,2205,396
Net worth3,8824,0304,0534,1144,2324,6754,796
Total debt634686536593535538573
Cash & bank38.0287.419.9068.4386.4780.3265.13
Net working capital315442325363390511510
Cash flow
Cash from operations46.1155.8124.17(52.90)227(1.51)197
Cash from investing21.68(79.64)96.5740.71(173)62.07(74.30)
Cash from financing(120)87.51(131)1.38(46.16)(70.53)(124)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue83.5957.0868.7239.6860.3062.8610697.04
Revenue growth (YoY)+38.6%-9.2%-35.2%-59.1%-35.4%-39.2%--
Other income3.7918.8928.837.1011.1737.425.47(8.01)
Total expenses83.1070.5967.7443.1855.8959.4385.5774.08
EBITDA0.49(13.51)0.98(3.50)4.413.4320.5322.96
EBITDA margin+0.6%-23.7%+1.4%-8.8%+7.3%+5.5%+19.3%+23.7%
Depreciation15.0015.3715.1515.1615.7916.4716.1016.48
Interest23.0421.7122.1423.5120.6120.2621.3117.77
Profit before tax(33.76)(31.70)(7.48)(35.07)(20.82)4.12(11.41)(19.30)
Tax(8.49)(7.79)(3.14)(11.94)(7.22)1.45(4.04)(6.02)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue507678851720653708716682
Revenue growth (YoY)-22.3%-4.3%+18.9%+5.5%-17.3%+35.2%--
Other income3.5618.1616.426.668.1124.757.977.67
EBITDA45.9658.39162113149138141140
EBITDA margin+9.1%+8.6%+19.0%+15.7%+22.8%+19.5%+19.7%+20.5%
Depreciation90.4290.6888.7984.4284.1381.3579.0971.97
Interest40.1037.0943.3045.7942.3342.7642.1248.78
Profit before tax(81.00)(51.22)46.13(10.44)30.5438.6727.7027.05
Tax(14.27)6.6624.392.53(34.73)15.26(15.39)22.42
Net profit(66.73)(57.88)21.74(12.97)65.2723.4143.094.63
EPS (β‚Ή)(4.26)(3.69)1.39(0.83)4.161.492.750.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,9322,7122,6162,4132,1411,9122,044
Revenue growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
Other income55.9421.6828.2127.7743.4238.4544.46
Total expenses2,3702,2612,3352,1291,8241,6601,546
Employee cost1,4471,2941,2081,030981873762
EBITDA562451280284317252498
EBITDA margin+19.2%+16.6%+10.7%+11.8%+14.8%+13.2%+24.4%
Depreciation339294311281308308283
Interest17415912085.6956.8147.6161.95
Profit before tax10519.31(122)(54.59)(4.25)(65.03)197
Tax7.4516.0731.19(24.79)(22.26)10038.69
Net profit98.68(18.28)(151)(8.36)49.61(170)163
Net profit margin+3.4%-0.7%-5.8%-0.4%+2.3%-8.9%+8.0%
EPS (β‚Ή)6.210.21(9.79)(1.90)1.15(10.53)10.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital31.3631.3631.3631.3631.3631.3631.38
Reserves & surplus6,6465,8005,5965,7785,5185,6675,684
Shareholders' funds (net worth)6,6775,8325,6285,8105,5495,6995,715
Minority interest0.000.000.000.000.000.000.00
Secured loans2,7302,0721,9461,8251,4211,166916
Unsecured loans346317366384409423442
Total debt3,0762,3892,3132,2091,8301,5891,357
Total liabilities10,9129,0628,7688,4197,8097,6047,367
Assets
Gross block12,41910,55110,3149,4638,6398,1617,896
Net block8,0767,0556,7246,1885,7735,6985,678
Capital work in progress5704676461,043780486234
Investments91.4597.39102249324172191
Inventories1,019900883804645516581
Sundry debtors673665484590473421577
Cash & bank balances991507413189172308161
Loans & advances143103124159256344353
Total current assets2,8262,1751,9051,7411,5461,5881,672
Total current liabilities999925774960700571689
Net working capital1,8271,2501,1317828461,017984
Total assets10,9129,0628,7688,4197,8097,6047,367
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash34126413211024412276.32
Net cash from operating activities491371379266355513585
Net cash from investing activities(245)(192)(225)(494)(619)(380)(442)
Net cash from financing activities201(102)(22.15)250130(11.04)(97.78)
Net change in cash44776.9813221.55(133)12245.62
Closing cash991507413189172308161
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.1%+3.7%+8.4%+12.7%+12.0%-6.4%-
EBITDA growth+24.6%+60.8%-1.3%-10.3%+25.7%-49.3%-
PBT growth+443.2%+9998.0%-124.0%-1184.5%+93.5%--36.1%
Net income growth+639.8%+87.9%-1707.3%-116.9%+129.1%-204.4%-
Revenue CAGR (3Y)+6.7%+8.2%+11.0%+5.7%+1.3%+4.1%+6.0%
EBITDA CAGR (3Y)+25.5%+12.5%+3.6%-17.0%-16.9%-17.3%+3.2%
Profitability & leverage
Net income margin+3.3%+0.1%-5.9%-1.2%+0.8%-8.6%+7.8%
Return on capital employed+2.8%+2.2%-0.0%+1.0%+0.8%+0.0%+3.7%
Return on net worth+1.6%-0.3%-2.7%-0.2%+0.9%-3.0%+2.9%
Debt / equity0.440.410.400.360.300.260.22
Long-term debt / equity0.250.170.170.220.180.120.08
Interest cover78.06101.51-393.342,573.27621.55-85.2228.86
Efficiency & per share
Fixed asset turnover0.260.260.260.270.250.240.28
Inventory turnover3.063.043.103.333.693.493.62
Debtors turnover4.384.724.874.544.793.834.00
EPS (β‚Ή)6.210.21(9.79)(1.90)1.15(10.53)10.10
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)425.82371.91358.90370.51353.89363.45364.25
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue83.5957.0868.7239.6860.3062.8610697.04
Revenue growth (YoY)+38.6%-9.2%-35.2%-59.1%-35.4%-39.2%--
Other income3.7918.8928.837.1011.1737.425.47(8.01)
Total expenses83.1070.5967.7443.1855.8959.4385.5774.08
EBITDA0.49(13.51)0.98(3.50)4.413.4320.5322.96
EBITDA margin+0.6%-23.7%+1.4%-8.8%+7.3%+5.5%+19.3%+23.7%
Depreciation15.0015.3715.1515.1615.7916.4716.1016.48
Interest23.0421.7122.1423.5120.6120.2621.3117.77
Profit before tax(33.76)(31.70)(7.48)(35.07)(20.82)4.12(11.41)(19.30)
Tax(8.49)(7.79)(3.14)(11.94)(7.22)1.45(4.04)(6.02)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue232400327403307200581
Revenue growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
Other income84.5232.9863.0552.1660.3966.1569.55
Total expenses226328324397274260407
Employee cost86.6390.1591.5486.1379.0458.2388.87
EBITDA5.3271.793.755.7632.52(59.32)174
EBITDA margin+2.3%+18.0%+1.2%+1.4%+10.6%-29.6%+29.9%
Depreciation62.5765.2010296.20140141141
Interest86.5270.4068.1957.9237.2334.1747.02
Profit before tax(59.25)(30.83)(103)(96.20)(84.39)(169)55.46
Tax(20.85)(20.96)(26.59)(37.33)(52.84)64.1216.94
Net profit(39.53)(11.18)(75.39)(56.08)(30.76)(235)42.58
Net profit margin-17.1%-2.8%-23.0%-13.9%-10.0%-117.5%+7.3%
EPS (β‚Ή)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital31.3631.3631.3631.3631.3631.3631.38
Reserves & surplus3,8513,9994,0214,0834,2004,6434,764
Shareholders' funds (net worth)3,8824,0304,0534,1144,2324,6754,796
Secured loans631658524590527526391
Unsecured loans3.5528.0311.743.557.8611.74181
Total debt634686536593535538573
Total liabilities--4,7874,9104,9465,2205,396
Assets
Gross block2,6552,6222,5732,4572,3392,3642,344
Net block1,3721,4011,4161,3821,3561,5101,633
Capital work in progress22.9740.7074.0514311812188.85
Investments2,8442,8412,8482,9133,0322,8822,900
Inventories155134170183197184214
Sundry debtors17117518414765.66119145
Cash & bank balances38.0287.419.9068.4386.4780.3265.13
Loans & advances310263210176196273284
Total current assets674659573574545656708
Total current liabilities359217248211154145197
Net working capital315442325363390511510
Total assets4,7674,8924,7874,9104,9465,2205,396
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash67.734.0514.0724.8816.3626.3328.00
Net cash from operating activities46.1155.8124.17(52.90)227(1.51)197
Net cash from investing activities21.68(79.64)96.5740.71(173)62.07(74.30)
Net cash from financing activities(120)87.51(131)1.38(46.16)(70.53)(124)
Net change in cash(51.80)63.68(10.02)(10.81)8.52(9.97)(1.67)
Closing cash38.0287.419.9068.4386.4780.3265.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-42.1%+22.1%-18.7%+31.3%+53.1%-65.5%-
EBITDA growth-92.6%+1814.4%-34.9%-82.3%+154.8%-134.2%-
PBT growth-92.2%+70.1%-7.1%-14.0%+50.0%--32.1%
Net income growth-253.6%+85.2%-34.4%-82.3%+86.9%-652.7%-
Revenue CAGR (3Y)-16.8%+9.3%+17.8%-11.5%-17.7%-25.0%+8.8%
EBITDA CAGR (3Y)-2.6%+30.2%--67.9%-44.8%-+5.4%
Profitability & leverage
Net income margin-16.6%-2.5%-23.3%-14.6%-10.3%-116.2%+6.6%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%+2.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%+0.9%
Debt / equity0.170.150.140.140.120.120.12
Long-term debt / equity0.050.050.040.040.030.030.04
Interest cover-151.131,068.29-69.68-64.04-34.62-17.03142.79
Efficiency & per share
Fixed asset turnover0.090.150.130.170.130.090.25
Inventory turnover1.602.631.862.121.611.012.66
Debtors turnover1.342.231.983.793.321.524.22
EPS (β‚Ή)(2.45)(0.63)(4.87)(3.75)(2.01)(14.85)2.46
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)247.59257.05258.46262.39269.88298.13305.66

Similar companies to Dishman Carbogen Amcis

Dishman Carbogen Amcis has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Dishman Carbogen Amcis

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Dishman Carbogen Amcis

The website of Dishman Carbogen Amcis (imdcal.com) receives about 16.7K visits a month.

  • Monthly visits
    16.7K

    ▼ 6.6% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Dishman Carbogen Amcis (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dishman Carbogen Amcis

DCAL: Q2 REVENUE 5.07B RUPEES VS 6.53B (YOY)
Exchange Update β€’ 7 days ago
DCAL: Q2 CONS NET LOSS 667.3M RUPEES VS PROFIT 652.7M (YOY)
Exchange Update β€’ 7 days ago
Dishman Carbogen: Co's Unit Successfully Finishes US FDA Inspection At Switzerland Facility With No Issues.
Exchange Update β€’ 2 months ago
Premium access

Complete news archive for Dishman Carbogen Amcis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dishman Carbogen Amcis

Dishman Carbogen Amcis was founded in 1983.

Dishman Carbogen Amcis is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Dishman Carbogen Amcis has 1,122 employees.

The primary company behind Dishman Carbogen Amcis, Dishman Carbogen Amcis Limited, reported revenue of β‚Ή2,988 Cr for FY 2026, up 8% year on year.

Dishman Carbogen Amcis was established in 1983 in Ahmedabad, India, by founder Janmejay R Vyas. Operations are centered on contract development and manufacturing services for active pharmaceutical ingredients within the pharmaceutical sector. Production facilities are maintained in India, supporting API synthesis and related processes for international clients. The focus remains on reliable manufacturing capabilities without additional diversification noted.

Dishman Carbogen Amcis's top competitors include Laurus Labs, Symbiotec and SeQuent.

Dishman Carbogen Amcis offers CRAMS Services, API Manufacturing, Analytical Capabilities, Finished Dosages, and Quaternary Salts.

Yes, Dishman Carbogen Amcis is publicly traded on NSE under the ticker symbol DCAL.

Dishman Carbogen Amcis operates through Dishman Carbogen Amcis Limited.

The legal entities of Dishman Carbogen Amcis currently have 8 directors, including Arpit Janmejay Vyas, Harshil Ramakant Dalal, Shrima Gaurangbhai Dave and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available